Related Experiment Videos
[Randomized controlled trials in Japan--lung cancer]
1Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 3, 2002
Summary
Standard lung cancer treatments in Japan include cisplatin combinations for advanced non-small cell lung cancer and small cell lung cancer. Concurrent chemoradiotherapy is established for localized disease, but adjuvant therapy for resected patients remains ineffective.
Area of Science:
- Oncology
- Clinical Research
Background:
- Lung cancer remains a significant global health challenge.
- Establishing effective treatment protocols is crucial for improving patient outcomes.
Purpose of the Study:
- To review and synthesize findings from randomized controlled trials on lung cancer treatments conducted in Japan.
- To identify established and emerging standard treatment modalities for non-small cell lung cancer and small cell lung cancer.
Main Methods:
- Systematic review of randomized controlled trials published after 1990, identified via PubMed.
- Inclusion of relevant papers presented at the American Society of Clinical Oncology annual meetings (1999-2002).
Main Results:
- Cisplatin combined with irinotecan or docetaxel is a standard treatment for advanced non-small cell lung cancer.
- Cisplatin plus irinotecan is established for small cell lung cancer.
- Concurrent chemoradiotherapy is a standard approach for localized small and non-small cell lung cancers.
Conclusions:
- Established standard treatments exist for various stages and types of lung cancer in Japan.
- Current evidence does not support any adjuvant treatment method for resected lung cancer patients as sufficiently effective.